Q3 2026 Elite Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Elite Pharmaceuticals Inc (ELTP) reported a significant increase in total revenues, reaching $31.6 million for the quarter, marking a 120% year-on-year increase.
- The company achieved a milestone by surpassing $100 million in revenues within the first three quarters of fiscal 2026.
- Gross profit for the three months ended December 2025 was $13 million, representing a 112% year-on-year increase.
- Elite Pharmaceuticals Inc (ELTP) has expanded its product line significantly, launching generics for several major products, including VYVANSE, TYLENOL with Codeine, and NORCO.
- The company maintains a strong balance sheet with working capital increasing to $84 million, an 83% increase from the beginning of the fiscal year.
- The company faces challenges in maintaining the same level of revenue growth in the future, as doubling revenues every year becomes increasingly difficult.
- Elite Pharmaceuticals Inc (ELTP) has experienced an increase in legal and professional costs due to expanded operations and compliance requirements.
- There are concerns about the impact of competition on pricing, particularly for generic products like Lisdex, which has seen price reductions.
- The company's accounts receivable has increased, with standard industry terms ranging from 60 to 90 days, impacting cash flow.
- Elite Pharmaceuticals Inc (ELTP) is not currently part of the FDA's PreCheck Pilot Program, which could fast-track domestic pharma manufacturing requests.
Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals third quarter of fiscal year 2026 conference call. (Operator Instructions)
Before management begins, the conference has the following statement. Elite would like to remind the listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties that are subject to change at any time, including, but not limited to, statements about Elite's expectations regarding forward-operating results. Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws and represent management's current expectations. Actual results may differ materially.
Elite disclaims any obligation to update or revise its forward-looking statements, except as required by law. More complete information regarding forward-looking statements, risks, and uncertainties can be found in the reports Elite files with the SEC, which is available on Elite's website at elitepharma.com, under the Investor Relations section. Elite encourages you to review these
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
